Randomized Controlled Trial of Intranasal Ketamine vs. Intranasal Midazolam in Individuals With OCD
Status:
Terminated
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
Obsessive-compulsive disorder (OCD) is a common illness that causes significant distress and
impairment. Currently, serotonin reuptake inhibitors (SRIs) are the only medications that are
FDA-approved to treat OCD. Unfortunately, SRIs can take a long time to work (2-3 months), and
even then they usually only partially reduce OCD symptoms. The present study, will test if
intranasal ketamine is feasible to use and can reduce OCD symptoms significantly more than a
comparison medication called midazolam. Therefore, you may or may not receive ketamine as
part of this study. Results from this study will allow doctors and researchers to better
understand if you and others with OCD may respond to this class of medications.